View article

High-dose chemotherapy with autologous stem cell transplantation (ASCT) is a common treatment strategy in lymphoma and myeloma, but no standard approach for the mobilization of peripheral hematologic stem and progenitor cells has been established. Levels of circulating CD34+ cells, a surrogate marker for mobilization efficiency, vary widely between pts, and may be influenced by disease state, prior therapy, and/or mobilization regimen. The Washington University (St. Louis, MO) transplantation database includes clinical parameters from 407 MM, 562 NHL, and 164 HD pts who received an ASCT (1995-2006). A retrospective analysis of this large (1133 pts) population was conducted to determine factors associated with mobilization efficiency. Mobilization failure was defined as collection of< 2× 10∧ 6 CD34+ cells/kg within 5 apheresis days. Statistical analysis included ANOVA with …